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Abstract
Intravenous phenylephrine (PE) is utilized commonly in critical care for cardiovascular support. Its impact on the
cerebrovasculature is unclear and its use may have important implications during states of critical neurological
illness. The aim of this study was to perform a scoping review of the literature on the cerebrovascular/cerebral
blood flow (CBF) effects of PE in traumatic brain injury (TBI), evaluating both animal models and human studies.
We searched MEDLINE, BIOSIS, EMBASE, Global Health, SCOPUS, and the Cochrane Library from inception to Jan-
uary 2020. We identified 12 studies with various animal models and 4 studies in humans with varying TBI pathol-
ogy. There was a trend toward a consistent increase in mean arterial pressure (MAP) by the injection of PE
systemically, and by proxy, an increase of the cerebral perfusion pressure (CPP). There was a consistent constric-
tion of cerebral vessels by PE reported in the small number of studies documenting such a response. However,
the heterogeneity of the literature on the CBF/cerebral blood volume (CBV) response makes the strength of the
conclusions on PE limited. Studies were heterogeneous in design and had significant limitations, with most fail-
ing to adjust for confounding factors in cerebrovascular/CBF response. This review highlights the significant
knowledge gap on the cerebrovascular/CBF effects of PE administration in TBI, calling for further study on the
impact of PE on the cerebrovasculature both in vivo and in experimental settings.




ylephrine (PE), is an alpha-1 adrenergic drug that is
used for systemic blood pressure support in a variety
of pathologies. It is one of the most commonly utilized
vasopressor agents for cardiovascular support in the
management of critically ill patients, through the mod-
ulation of adrenergic receptors.1 PE is well known as an
effective vasopressor that triggers vascular constriction
and increases blood pressure.2
Emerging methods of biomedical signal processing
for recorded cerebral perfusion pressure (CPP) and in-
tracranial pressure (ICP) monitoring have led to tar-
geted patient therapies, with the goal of improving
patient outcomes in traumatic brain injury (TBI)
based on continuous measures of cerebrovascular reac-
tivity.3,4 Vasopressors, including PE, are used to treat
patients with critical neurological illness, such as TBI,
with the aim of targeting specific mean arterial pressure
(MAP) and CPP goals.1,5 However, it remains unclear
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if PE is detrimental to end-organ cerebral perfusion, or
leads to impairment of cerebral autoregulation. Such
impacts may have important connotations for out-
comes in critically ill patients with TBI, as the effective
mediation of cerebral blood flow (CBF) or cerebrovas-
cular reactivity may be vital.6–9 As such, understanding
the impact of exogenously administered PE on cerebro-
vascular reactivity and CBF is crucial, as individualized
care and personalized targets based on cerebral autor-
egulation and cerebrovascular response are emerging
in management strategies for TBI.8–13
The goal of this study was to perform a systematic,
scoping review of the available literature on the im-
pact of PE on cerebrovascular/CBF response in animal
models and human subjects with TBI.
Methods
A systematic review of the literature was conducted using
the methodology outlined in the Cochrane Handbook
for Systematic Reviewers.14 The data were reported in
line with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA).15 Supplemen-
tary Appendix S1 provides the PRISMA checklist.
The review questions and search strategy were decided
on by the supervisor (F.A.Z.) and primary author (L.F.).
Search question, population,
and inclusion/exclusion criteria
The question posed for systematic review was: What is
the effect of exogenous systemically administered PE
on the cerebrovascular response/CBF in TBI? All stud-
ies (animal or human), prospective and retrospective,
of any size were included.
The primary outcome measure was the impact on
objectively measured CBF or the cerebrovascular
responsiveness (i.e., cerebral vasoconstriction or cere-
bral autoregulation/cerebrovascular reactivity) as docu-
mented by: autoradiographic diffusible tracer technique,
freely diffusible tracers, thermal diffusion probe, clear-
ance method, laser-Doppler flow probe, flow trans-
ducer, flow meter, visual recording software, or any
other objective means of CBF determination (including
imaging-based techniques). Secondary outcomes in-
cluded adverse effects of PE administration, including
systemic or cerebral end-organ complications.
All studies whether prospective or retrospective,
of all sizes, of any age category, and with the use of
PE with formal documentation of cerebrovascular re-
sponse/CBF during administration in the setting of
TBI, were eligible for inclusion in this review. Exclusion
criteria were: a non-English language study, non-TBI
animal model, non-TBI human cohort, or CBF media-
tion with substance other than PE.
Search strategy
MEDLINE, BIOSIS, EMBASE, Global Health, SCO-
PUS, and the Cochrane Library from inception to Jan-
uary 2020 were searched using individualized search
strategies for each database. The search strategy for
MEDLINE can be reviewed in Supplementary Appen-
dix S2; a similar search strategy was used for the other
databases. In addition, the reference lists of reviewed
articles on the cerebral blood vessels/CBF response to
PE were examined to ensure no references were left out.
Study selection
Using two reviewers (L.F. and J.D.), a two-step review
of all articles returned by our search strategy was per-
formed. First, the reviewers independently screened all
titles and abstracts of the returned articles to decide
whether they met the inclusion criteria. Second, full text
of each returned article was assessed to confirm whether
it met the inclusion criteria and that the primary outcome
of cerebrovascular/CBF response to PE was documented.
Third, the attained literature was separated into TBI ver-
sus non-TBI models. Any discrepancies between the two
reviewers were resolved by a third party (F.A.Z.).
Data collection
Data were extracted from the selected articles and stored
in multiple electronic databases to ensure data integrity.
Animal studies
Data abstraction fields included the following: number
of animals, type of study, animal model characteristics,
the goal of the study, type of vasopressors adminis-
tered, dose of vasopressors administered, technique of
CBF/vasculature assessment, cerebrovascular/CBF re-
sponse to PE, other outcomes, and general conclusions.
Human studies
Data fields included the following: number of patients,
study type, article location, mean age, patient charac-
teristics, goal of the study, dose, dose duration, tech-
nique to measure cerebrovascular/CBF response, the
documented cerebrovascular/CBF response, other out-
comes, and conclusion.
Statistical analysis
A meta-analysis was not performed in this study be-
cause of the heterogeneity of model types, study de-
signs, and data.




Search results and study characteristics
The results of the search strategy across all databases
and other sources are summarized in Figure 1. Over-
all, 2315 articles were identified from the databases
searched. Removed were 1246 articles because of dupli-
cate references, leaving 1069 to review. By applying the
inclusion/exclusion criteria to the title and abstract of
these articles, we identified 261 articles that fit these cri-
teria. No articles were added from reference sections of
pertinent review articles, leaving a total of 261 articles
to review. On applying the inclusion/exclusion criteria
to the full-text documents, only 16 articles were found
eligible for inclusion in the systematic review, all from
the database search. Articles were excluded because
they either did not report details around objectively
measured cerebrovascular/CBF response to PE admin-
istration, were review articles, were non-relevant, or
contained non-TBI cohorts.
Part 1: TBI animal models
Tables 1 and 2 outline the animal TBI study character-
istics and cerebrovascular/CBF responses, respectively.
Of the 12 articles that had animal models with TBI, the
following models were described: induced fluid per-
cussion injury,16–22 impact-acceleration injury,23 rapid
FIG. 1. PRISMA (Preferred Reporting in Systematic Reviews and Meta-Analysis) flow diagram of search
results and filtering.












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































axial head rotation,24,25 and rod directed into the pari-
etal cortex.26,27 To measure cerebrovascular/CBF re-
sponse, a variety of techniques were used including:
comparing ICP (found with strain gauge or catheter
transducer—a surrogate metric for pulsatile cerebral
blood volume [CBV]) and partial or region oxygenation
(found with near infrared spectroscopy or blood sam-
ples), thermal diffusion probes, cortical laser Doppler
flowmetry and direct measurement of vasculature
change, or change in cerebral tissue weight (i.e., as a
metric of CBV). There were 10 studies that used
swine models and 2 that used rats.23,26 Of the swine
model studies, 5 were conducted on newborn
pigs,16–18,24,25 one had juvenile models,22 and the
remaining 4 did not specify age (but were assumed to
be pre-adult based on weight).19–21,27 The majority
of studies controlled for both PO2 and PCO2, while
administering heavy sedation.
CBF/CBV response. A clear and consistent increase in
CPP was noted in all studies in which subjects had PE
injected systemically.16,19–22,24–27 However this change
did not always translate to an increase in CBF or ICP
(a surrogate measure of CBV), shown by the lack of im-
pact on ICP and CBF in two studies.21,25 In the studies
in which cerebral autoregulation was impaired, there
was a significant increase in ICP and CBF caused by
PE injection (cerebral autoregulation was impaired
with a fluid percussion injury).16–18,22 These studies
evaluated the CBF before and after injury, as well as be-
fore and after PE injection, with CBF increasing to-
ward16 or exceeding baseline values post-injection.17,18,22
One study evaluated cerebral autoregulation (direct vi-
sual change in pial blood vessels) during PE injections,
with cerebral autoregulation becoming impaired in
male piglets only.16 Further, in the setting of a trau-
matic impact (rod injected to a deformation of 3 mm
in parietal cortex) with sodium nitroprusside infusion,
a decrease in CBF and ICP occurred, which was then
reversed with PE injection back to near baseline val-
ues.26 In a study utilizing systemic injection of PE,
and that measured brain tissue mass change, there
was a direct increase in tissue volume mass (correlated
with CBV).23
Direct effect on cerebral vessels. The studies that
measured the direct effect of PE on cerebral vessels
were all neonatal models. Similar effects of PE in
these studies were shown within cerebral vessels, with
all studies that measured cerebrovascular diameter or
tension demonstrating cerebral vasoconstriction. In
two studies, PE was injected directly through a cranial
window on the vessels, demonstrating a reduction in
pial artery diameters.17,22 One study that used the cra-
nial window technique, but utilized systemic injection
of PE, found mixed results to vessel change.16 Another
study found that pial arterial diameter decreases in
male piglets during systemic PE injection, but increases
in female piglets.18
Part 2: TBI human models
Tables 3 and 4 outline the human TBI study character-
istics and cerebrovascular/CBF responses, respectively.
There are four studies with human patients with TBI
who were injected with PE, and had CBF or cerebrovas-
cular responses measured.28–31 One study did not spec-
ify the ages of the patients, who had a Glasgow Coma
Scale (GCS) score £8.28 The other three studies all
had patients with mean ages of 30–35 years. Of these
three studies, one had patients with a GCS score be-
tween 3 and 14,29 one had patients with diffuse brain
injury and a GCS score £12,30 and one had patients
with a mean GCS score of 5.5 and an injury severity
score of 37.31 In these studies, CBF was measured
with the 133Xenon inhalation method,28,29 the arterial
jugular difference in oxygen,30 or computed tomog-
raphy (CT) perfusion.31 Most studies adjusted for
PCO2 but failed to mention whether PO2was controlled.
Sedative regiments for these studies were not clearly
indicated.
CBF/CBV response. All studies objectively docu-
mented the CBF response to PE injection in human pa-
tients with TBI. One study demonstrated an increase in
CPP, with concordant MAP increase.30 The CBF re-
sponse in this study varied and was inconsistent across
the population, demonstrating both increases and de-
creases. A second study failed to demonstrate a signif-
icant change in CBF or ICP (i.e., surrogate of pulsatile
CBV).31 A third study compared patients with intact
versus impaired cerebrovascular reactivity (measured
by the percentage change in CPP/CBF with the clear-
ance method) and found that PE substantially in-
creased CBF, by up to 53%, when regulation was
impaired versus not impaired.28 Regarding the CBV re-
sponse to PE administration, an effect on ICP was
also shown, with those displaying impaired cerebro-
vascular reactivity having a higher mean change in
ICP of 3.8 mm Hg versus 1.5 mm Hg to PE injec-
tion, for the impaired versus intact groups, respectively









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(cerebrovascular reactivity was consider intact if an in-
crease in CPP did not change CBF as measured by CT
perfusion).31
Cerebrovascular response. No human study measured
the direct cerebrovascular response to PE in human sub-
jects. Despite this, there were some studies that attemp-
ted to quantify cerebrovascular resistance (CVR) from
the CPP/CBF relationship.28,30 However, there was no
consensus on the CVR response to PE administration,
with CVR demonstrating a variable response.
Adverse events to phenylephrine in all models
The adverse effects of PE in animal models included:
bradycardia, vascular hyperresponsiveness in the late
stages of vasodilatory shock, tachycardia, arrhythmia,
increased myocardial oxygen consumption, and ische-
mia.19,23 One study showed an increased expression of
cerebral V1 receptor subtype after TBI, and the subse-
quent formation of cerebral edema.19 In two studies,
one animal and one human, cerebral autoregulation
was impaired with PE administration (i.e., there was
an in-phase direct increase in CBF with increased
MAP).17,28 Impaired autoregulation appeared to dem-
onstrate a sex predominance in another study, which
found PE induced impaired autoregulation preferen-
tially in male neonatal pigs, as compared with fe-
males.17
Discussion
PE is a commonly used vasopressor agent to increase
MAP in a variety of treatment practices. In critical
care patients, and specifically those with TBI, PE may
be utilized in targeting of ICP, CPP (and hopefully
CBF) to improve outcomes. Knowledge of the cerebro-
vascular response to various commonly utilized vaso-
pressor agents, such as PE, is crucial for the provision
of effective treatments in TBI.4,6–11,13,32,33 The current
literature on the cerebrovascular effects of PE leaves
uncertainty in predicting the cerebrovascular/CBF
response to its administration. Through our scoping
review we attempted to gather all studies that docu-
mented the administration of PE and measured its ef-
fects on the cerebrovascular response/CBF, in both
animal models and human subjects afflicted with
TBI. Some important points and preliminary trends
can be gleaned from this review, although it must be ac-
knowledged that, overall, the literature in this area is
limited, highlighting a significant knowledge gap.
First, PE injection leads to a direct increase in MAP,
and subsequently CPP. MAP increase is reported in all
studies regardless of design or method, and subse-
quently led to a CPP increase in all studies that concur-
rently evaluated ICP. This general finding is not
surprising, as the main role for PE in critical neurolog-
ical illness is the augmentation of MAP and CPP. Par-
ticularly, in the treatment of moderate/severe TBI, this
aspect of PE is attractive and is employed to maintain
ICP/CPP targets, as suggested by current guideline-
based therapies.4,34 However, the exact dose-response
relationship between MAP and CPP was not clearly de-
lineated in many studies, particularly in the human
studies. As we transition to personalized physiological
targets in TBI care, such as optimal CPP,10,11,13 we
may find ourselves targeting CPP values well above
the current Brain Trauma Foundation defined target
range of 60–70 mm Hg.4 As such, with increasing PE
dosing, the relationship between PE dose, MAP, and
subsequently CPP may prove to be non-linear. In
fact, with escalating doses of PE and the subsequent in-
crease in MAP, there is the potential to overwhelm ce-
rebrovascular reactivity and cause degeneration of the
classic Lassen autoregulatory curve.35 This would ex-
pose patients to significant secondary injury, and
poor long-term outcomes, as reported in the human
TBI literature.7,33,36–38 The current literature in both
animal and human TBI fails to inform whether such
an upper limit of PE dosing exists. It is likely the spe-
cific dose-response is dependent on a variety of individ-
ual factors, including genotype.39 Thus, despite the
similar results seen with PE administration in both an-
imal and human TBI studies, a true understanding of
its impact on the cerebral vasculature remains limited,
necessitating future investigation.
Second, there were a limited number of TBI animal
model studies that measured directed cerebral vessel
response, with only four studies in neonate piglet mod-
els.16–18,22 The literature lacks homogeneity in model
type and study design. However, PE administration
demonstrated consistent constriction of the cerebral
vessels. It must be acknowledged though that the ability
to translate cerebrovascular responses to PE in imma-
ture neonatal vessels to mature adult cerebral vessels
is limited. Despite the clear limitations of these data,
there is sufficient homogeneity in the outcome to sug-
gest that PE has a direct vasoconstrictive effect on the
cerebral pre-capillary arterioles. This suggested effect
is important; given the strong independent association
between impaired cerebrovascular reactivity and poor
Froese et al.; Neurotrauma Reports 2020, 1.1
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patient outcome in TBI,37,38 it is clear that cerebrovas-
cular reactivity is an important aspect of cerebral physi-
ology that impacts secondary injury exposure and
outcome. Administration of vasoactive compounds
such as PE may directly impact cerebrovascular reac-
tivity, given cerebrovascular reactivity is believed to
occur at the pre-capillary arteriole level.35,40–42 As
highlighted in this review, literature on an exact
dose-response at the pre-capillary arteriole and its
impact on continuously measured cerebrovascular re-
activity is absent. Therefore the impact of continuous
PE dosing on cerebrovascular reactivity in TBI remains
unclear, supporting the need for future research.
Third, despite the general increase in CPP, the quan-
titative CBF response in human models was underin-
vestigated. Of the two studies that showed a CBF
increase with PE injection, either autoregulation was
impaired,28 or there was a conflicting increase and sub-
sequent decrease in CBF.30 The animal literature also
demonstrated an increase in CBF. However, in the
study design PE was never the sole focus of the study,
with other medications co-administered, leading to sig-
nificant confounding. Without a true understanding of
the impact of PE on the pre-capillary vascular response,
and subsequently CBF, we remain in the dark regard-
ing safe dosing ranges in TBI.
Finally, within the literature it is unclear what the
impact of systemic PE injection is on cerebrovascular
reactivity/cerebral autoregulation in animal/human
TBI, as there were no studies identified that evaluated
the cerebral microvascular change within human
models. Thus, it remains unknown if there exists a
dose-response effect on cerebral autoregulation, where
specific PE dose ranges may lead to impaired autoregu-
lation. The animal literature adds insight to the effects
of PE on cerebral vessels as reported in four studies in
which PE injected systemically or locally found vessels
to constrict.16–18,22 Further, one animal study suggested
a potential disparity in autoregulatory response to PE
based on sex, with males displaying deterioration in ce-
rebral autoregulation caused by PE injection.17 How-
ever, the lack of direct translation of these data to
human models and patient care leaves limitations to
be addressed in future studies. Also, there was a lack
of consistency in evaluating cerebral autoregulation.
Within the human studies alone, there were three dif-
ferent methods used to evaluate if cerebral autoregula-
tion was intact. A refined and accurate way to quantify
cerebral autoregulation in vivo is needed. Such autore-
gulatory monitoring should take the form of commonly
adopted continuous measures of cerebrovascular reac-
tivity, such as pressure reactivity index (PRx).
Thus, overall, given the outlined trends and limita-
tions of the identified literature in this area, we are
left with an inconclusive view of the impact of PE on
CBF/cerebrovasculature in TBI. But a ‘‘negative’’ or ‘‘in-
conclusive’’ systematic review does provide important
information regarding the current gap in knowledge.
Despite PE being a commonly administered vasoactive
compound in neurocritical care, we have a limited idea
of its impact on the end organ of our primary interest,
the brain. Aside from the general increase in MAP and
trend toward an increase in CVR, when measured,
the impact on cerebral autoregulation/cerebrovascular
reactivity and CBF is unclear. Such a glaring hole
in the available TBI literature is both important to
identify/quantify—which we believe this review has
done—and represents an area where future research
is of utmost importance (see ‘‘Future directions’’ sec-
tion for more details). As such, despite the limited
conclusions drawn here, we believe highlighting such
limitations/deficiencies will lead to future directed
study of the cerebral impacts of PE.
Limitations
Although this review is comprehensive, there exist sig-
nificant limitations. First, the overall literature was very
heterogeneous in design. This limits how definitive we
can be in our statements regarding the impact of PE on
CBF, and cerebrovascular response in TBI. Similarly,
there was heterogeneity in the co-administration of va-
soactive compounds, sedative regimens, and documen-
tation of PCO2 and PO2 levels during measurement of
CBF/cerebrovascular response. Also, the heterogeneity
in CBF/cerebrovascular response measurement tech-
niques between studies further limits our ability to
consolidate findings between studies. Thus, the conclu-
sions regarding the impact of PE on CBF/cerebrovascular
response lack strength. Second, animal models do not
necessarily translate directly to human response to
PE. Therefore, despite a larger volume of literature on
animal TBI models, it remains unknown if any of the
data can directly translate to human patients. Similarly,
some models focused on young or neonatal animals, in
which it is known that the cerebrovasculature is in an
immature state. The response of such vessels to PE ad-
ministration may not reflect the true response in ma-
ture animals, or adult humans. As such, we are again
limited in our ability to extrapolate results. Third, the
disparity in response shown in CBF to PE
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administration limits our ability to confidently state the
impact of PE on CBF, both in animals and humans
afflicted with TBI. This is further clouded by the differ-
ent populations and models studied. Finally, almost all
studies identified, both animal and human, failed to
focus on the cerebrovascular response of the pre-
capillary arterioles to PE administration. The animal
studies that did utilized neonatal models. These pre-
capillary arterioles, which are believed to be the
major players in cerebral autoregulatory response,
may behave differently in neonates as compared with
adults. Knowledge of the impact of PE on such vessels
is crucial, as impaired cerebrovascular function is a
known associate of poor outcome in the setting of TBI.
Future directions
Through this review of the literature on the effect of PE
on CBF/cerebral vessel response, we found a trend to-
ward an increase in MAP, CPP, and CVR across all an-
imal models and human subjects with TBI. However,
the CBF/cerebrovascular response remains unclear,
given the disparity in responses shown. Despite the
limited concrete conclusions on the impact of PE on
TBI derived, this review has highlighted an important
knowledge gap related to a readily administered vaso-
active compound in neurocritical care, and we have
outlined future avenues that require investigation.
Future work on PE and the cerebrovascular response
should focus on the dose response in both animals and
humans, evaluating regional disparities in vascular
response across the age spectrum and between sex
groups, and on the pre-capillary arterioles responsible
for cerebral autoregulation. Human TBI research
would benefit from multi-center and comprehensive
high-frequency physiological data sets. Such data
would include accurate and complete treatment mark-
ups linked to high-frequency physiology, allowing
assessment of the impact of PE administration/dose
changes on various aspects of cerebral physiology.
The high-frequency physiology data sets would need
to comprise full waveform data, allowing for advanced
bio-signal analytics, and derivation of continuous mea-
sures of cerebrovascular reactivity and compensatory
reserve. Similarly, the monitoring modalities employed
in this human TBI population would ideally include
not only ICP/ICP-derived metrics, but also measures
of end-organ CBF (such as regional thermal diffusion
probes or multi-channel near infrared diffuse correla-
tion/time-resolved spectroscopy), end-organ oxygen
delivery (through brain tissue oxygen probes or
near infrared spectroscopy), and cerebral metabolism
(through microdialysis). Further, with all monitoring
in place, manipulations in PE dosing would need to
occur, to ensure a comprehensive understanding of
the impact of changes in PE on cerebrovascular physi-
ology in vivo.
We envision the experimental animal model work
employing both healthy controls and TBI models. An
important aspect of such future investigations would
be controlling/adjusting for potential confounders.
This would require uniform sedation regimens and
accurate control of PCO2/PO2. Evaluation of CBF/
cerebrovascular response in such animal models
would benefit from continuous high-temporal fre-
quency methods, using clinically applied multi-modal
monitoring/signal processing techniques. Such moni-
toring could, in theory, deploy multiple monitors si-
multaneously, assessing regional CBF, cerebrovascular
reactivity, oxygen delivery (using brain tissue oxygen
probes or advance near infrared spectroscopy monitor-
ing), and metabolics (using microdialysis). Within the
TBI models, given regional disruption in blood–brain
barrier integrity, such high-temporal and spatial con-
tinuous monitoring is crucial, as regional disparities
in CBF/cerebrovascular response post-TBI may be
driven by regional differences in blood–brain barrier
functionality. This research should involve the applica-
tion of multi-modal cerebral physiological monitoring,
and the derivation of continuous metrics of cerebrovas-
cular reactivity.
Finally, both human and animal research would
benefit from concordant genotyping and assessment
of vascular protein/vasoactive small-molecule bio-
markers associated with cerebrovascular control.43
The outlined multi-faceted, comprehensive approach
to monitoring is the only way to improve understand-
ing of the impact of PE administration on CBF/
cerebrovascular response in TBI. Such investigations
are the ongoing aspirations/work of various Europe-
an,44 North American,45–50 and Canadian51 collabora-
tive efforts.
Conclusion
In TBI, the human and animal literature on the cere-
brovascular/CBF effects of PE is scarce and signifi-
cantly limited. Limitations include study and model
design heterogeneity and failing to adjust for potential
confounders. The identified literature demonstrated a
trend toward increased MAP, CPP, and CVR with PE
administration. The direct cerebrovascular response
Froese et al.; Neurotrauma Reports 2020, 1.1
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to PE administration demonstrated cerebral vasocon-
striction in TBI animal models. However, the CBF re-
sponse to PE administration was heterogeneous, in
both animal and human studies identified, with no de-
finitive conclusions. This review highlights a major
knowledge gap regarding the impact of PE in TBI. Fur-
ther research into the CBF and pre-capillary arteriole
response to PE administration in TBI is required, as
it carries important implications for treatment in
moderate/severe TBI.
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